Vexim SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vexim says SpineJack’s CE Mark expanded to all types of vertebral compression fractures
Vexim SA:Says it has obtained approval in Europe to extend SpineJack system's indications to all types of vertebral compression fractures.
Latest Developments for Vexim SA
- Vexim announces 12-month results of study of performance of SpineJack in treating acute fresh traumatic vertebral compression fractures
- Vexim SA announces results of study into use of Spinejack for vertebral compression factors
- Vexim SA announces results of study of SpineJack
- Vexim SA Announces Results of Retrospective Study of SpineJack
Latest Key Developments in Medical
- IDEXX Laboratories Inc raises FY 2014 revenue outlook; reaffirms FY 2014 EPS outlook
- Ocular Therapeutix Inc prices initial public offering
- C R Bard Inc gives Q3 2014 guidance; EPS guidance in line with analysts' estimates; raises FY 2014 EPS guidance; gives FY 2014 revenue guidance above analysts' estimates - Conference Call
- Uroplasty Inc reaffirms FY 2015 guidance - Conference Call
- Share this
- Digg this